Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial

INTRODUCTION: We evaluated the cost-effectiveness of linagliptin in Japan by estimating the lifetime outcome based on clinical event rates from the Asian subpopulation of the CARMELINA trial. In CARMELINA, linagliptin added to standard of care (SoC) versus SoC demonstrated noninferiority with regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Watada, Hirotaka, Sakamaki, Hiroyuki, Yabe, Daisuke, Yamamoto, Fumiko, Murata, Tatsunori, Hanada, Keigo, Hirase, Tetsuaki, Okamura, Tomoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376765/
https://www.ncbi.nlm.nih.gov/pubmed/32557283
http://dx.doi.org/10.1007/s13300-020-00852-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376765/
https://www.ncbi.nlm.nih.gov/pubmed/32557283
http://dx.doi.org/10.1007/s13300-020-00852-8

Ejemplares similares